



## Opinion piece



**Cite this article:** Loewe A, Hunter PJ, Kohl P.

2025 Computational modelling of biological systems now and then: revisiting tools and visions from the beginning of the century.

*Phil. Trans. R. Soc. A* **383**: 20230384.

<https://doi.org/10.1098/rsta.2023.0384>

Received: 30 April 2024

Accepted: 15 July 2024

One contribution of 8 to a theme issue ‘Science into the next millennium: 25 years on’.

### Subject Areas:

computational biology, computer modelling and simulation, medical computing, biomedical engineering, biomathematics, mathematical physics

### Keywords:

*in silico* medicine, modelling and simulation, artificial intelligence, *in silico* clinical trials, cardiology

### Author for correspondence:

Axel Loewe

e-mail: [axel.loewe@kit.edu](mailto:axel.loewe@kit.edu)

# Computational modelling of biological systems now and then: revisiting tools and visions from the beginning of the century

Axel Loewe<sup>1</sup>, Peter J. Hunter<sup>2</sup> and Peter Kohl<sup>3</sup>

<sup>1</sup>Institute of Biomedical Engineering, Karlsruher Institut für Technologie, Karlsruhe, Germany

<sup>2</sup>Bioengineering Institute, University of Auckland, Auckland, New Zealand

<sup>3</sup>University of Freiburg, Medical Faculty, Institute for Experimental Cardiovascular Medicine, University Heart Center Freiburg · Bad Krozingen, and Faculty of Medicine, University of Freiburg, 79110 Freiburg, Germany, Freiburg, Germany

AL, 0000-0002-2487-4744; PJH, 0000-0001-9665-4145; PK, 0000-0003-0416-6270

Since the turn of the millennium, computational modelling of biological systems has evolved remarkably and sees matured use spanning basic and clinical research. While the topic of the peri-millennial debate about the virtues and limitations of ‘reductionism and integrationism’ seems less controversial today, a new apparent dichotomy dominates discussions: mechanistic versus data-driven modelling. In light of this distinction, we provide an overview of recent achievements and new challenges with a focus on the cardiovascular system. Attention has shifted from generating a universal model of the human to either models of individual humans (digital twins) or entire cohorts of models representative of clinical populations to enable *in silico* clinical trials. Disease-specific parametrization, inter-individual and intra-individual variability, uncertainty quantification as well as interoperable, standardized and quality-controlled data are important issues today, which call for open tools, data and metadata standards, as well as strong community interactions. The quantitative, biophysical and highly controlled approach provided by *in silico* methods has become an integral part of physiological and medical research. *In silico* methods have the potential to accelerate future progress also

in the fields of integrated multi-physics modelling, multi-scale models, virtual cohort studies and machine learning beyond what is feasible today. In fact, mechanistic and data-driven modelling can complement each other synergistically and fuel tomorrow's artificial intelligence applications to further our understanding of physiology and disease mechanisms, to generate new hypotheses and assess their plausibility, and thus to contribute to the evolution of preventive, diagnostic and therapeutic approaches.

This article is part of the theme issue 'Science into the next millennium: 25 years on'.

## 1. Embracing the mountain and village views

The pursuit of understanding biological systems through computational modelling and simulation (M&S) makes use of a multitude of approaches, each providing a specific lens through which intricate mechanisms governing life can be observed. In 2000, Kohl *et al.* described tools and visions for computational modelling of biological systems in the twenty-first century [1]. At the turn of the millennium, they likened their exploration to the contrasting perspectives of the mountain and village views, introduced in an old Chinese parable.

*The wise man walks from the village to the top of the nearby mountain and, after a brief and peaceful rest, strides back to the village. There he stays for a short while, before he returns to the mountain, and so on. Asked why he does this, he replies that he wants to understand his people. But when he dwells inside the village, he can't see the whole of it, and when he is on the summit, he is out of touch with the villagers. So he continues his pilgrimage for eternity.*


Much like an observer standing atop a mountain, computational modellers often aim for a panoramic vista, seeking overarching principles and comprehensive insights that capture the concepts of biological phenomena. This integrative perspective offers a broad overview, enabling the identification of fundamental principles governing complex biological systems. However, it also entails abstraction, potentially overlooking finer nuances and intricacies inherent in the biological fabric.

Conversely, akin to an inhabitant of a village intimately familiar with its every nook and cranny, certain modelling approaches delve deeply into specific biological mechanisms, exploring their intricacies with unparalleled detail. This reductionist close-up view provides an in-depth and potentially mechanistic understanding of localized processes, allowing for precise examination and manipulation. Yet, it may come at the cost of losing sight of the interconnectedness and holistic behaviour exhibited by the broader biological system.

The discourse between these contrasting perspectives—the panoramic vantage point from the mountain (integrationism) and the intimate familiarity within the village (reductionism)—has settled to a certain degree and the valuable contributions of both views are appreciated now, while a new apparent dichotomy emerges: data-driven versus mechanistic modelling. In this article, we embark on a journey that tries to navigate these (seemingly) contrasting approaches, exploring how they diverge, converge and synergize in advancing our understanding of physiology, i.e. the 'logic of life' with a focus on the cardiovascular system. This work covers both basic research about fundamental physiology, and applications of *in silico* models to solve real-world problems as we believe they are closely intertwined: as one applies knowledge to solve problems, one learns about shortcomings of the fundamental theory, especially in complex (e.g. biological systems).

## 2. The millennium view from today's perspective

The vision presented by Kohl *et al.*, [1] has proven to be remarkably accurate overall. Today, computational M&S have matured significantly, witnessing widespread adoption in both basic and clinical research, as evident in the increasing number of publications utilizing *in silico* tools. The



**Figure 1.** Synergy of mechanistic and statistical (data-driven) models. Reproduced from Corral-Acero *et al.* [12] under the Creative Commons Attribution License 4.0.

ratio of PubMed-listed cardiology studies using M&S is continuously rising and has multiplied fivefold since 1990 (2023: 2.2%).<sup>1</sup> The advantages initially highlighted, including faster and more cost-effective research, arbitrary resolution within the model's scope and enhanced availability, remain true and have advanced over time.

The Physiome project, initiated in the 1990s with the vision of developing a comprehensive understanding of a healthy human [2], progressed further, and within 10 years it had already started incorporating genetic inheritance and environmental influences [3,4]. In the first decade of this millennium, the virtual physiological human (VPH) concept emerged [5]. The Physiome project specifically, but also the wider domains of systems biology, personal health systems, biomedical informatics and systems pharmacology, all face the common challenge of integrating complex and diverse data and models. Today, the focus has shifted from a singular model of 'the human' to disease-specific models and variability within cohorts, akin to marking continuous transitions between the village and mountain views. However, in certain aspects, the enthusiasm surrounding computational M&S has proven to be overly optimistic. The importance of reliable and relatable high-quality data, as opposed to sheer data quantity, has become evident in the journey from the village to the mountaintop. Considerations such as species-specific [6], sex-specific [7], age-specific and disease-specific modelling have been acknowledged, requiring more concerted efforts and coordination between *in silico*, *in vitro*, *in vivo* and demographic data acquisition, processing and sharing.

The advent of new experimental methods and the rise of machine learning [8–11] have introduced an apparent dichotomy between mechanistic and data-driven approaches. Data-driven models seem to navigate a cloudy summit, while mechanistic models dwell in the village. Both possess the potential for integration, as data-driven models can be hypothesis proffering (mountain-to-village information transfer), while mechanistic models, especially when bridging multiple scales (temporal, spatial, species, disease, etc.) can offer relevant data input (village-to-mountain information transfer). With the latter being built upon first principles, they are more likely to generalize well and respect fundamental laws of physics. The former, however, are directly linked to real-world observations and thus more likely to capture important phenomena of

<sup>1</sup>Search query: (atria\*[Title/Abstract] OR ventric\*[Title/Abstract] OR cardi\*[Title/Abstract]) AND ('comput\* model'[Title/Abstract] OR 'mathematical model'[Title/Abstract] OR 'in silico'[Title/Abstract]) vs (atria\*[Title/Abstract] OR ventric\*[Title/Abstract] OR cardi\*[Title/Abstract]).

*in vivo* (patho-)physiology. Looking to the future, we need to integrate data-driven and mechanistic modelling approaches, as visualized in figure 1, more systematically in order to use the full potential of both.

The societal benefits of computational M&S, outlined at the turn of the millennium [1], are increasingly tangible. From serving as teaching tools to aiding decision-making in clinical trials, computational models see adoption into practice. During the COVID-19 pandemic, M&S (mostly data-driven) became invaluable [13]. When it comes to standardizing and individualizing medical care, there is still a long way to go, in spite of initial success stories. The millennial promise of reducing morbidity and mortality turned out to be true: life expectancy in the EU rose from 80.9 in 2002 to 84.0 years for women in 2019 (before the pandemic) and from 74.3 to 78.5 years for men. However, we are not aware of data that would allow one to quantify the contribution of M&S to this improvement. Accepted contributing factors include a reduction in infant mortality, rising living standards, improved lifestyles and better education, as well as advances in healthcare and medicine in general [14].

The following sections provide perspectives on M&S applications in basic and translational research, digital twins, *in silico* clinical trials and machine learning.


### (a) Utilization of modelling and simulation in basic, and translational research

The last few decades have witnessed improved cross-fertilization between wet lab/clinical and computational methods in basic and translational research. Novel experiments and methods [15] have contributed to the generation of unprecedented data for M&S applications in terms of both quantity and quality. In turn, *in silico* experiments have not only yielded novel, experimentally testable hypotheses but also served to falsify hypotheses derived from experimental or clinical observations [16]. The conceptual framework, mathematics and technology underpinning and enabling models have evolved. Often, this evolution was iterative and continuous, for example enhancing resolution, expanding the ‘field of view’ from tissue patches to whole organs, and extending timescales, but the field has also seen a number of disruptive changes, such as explicit representations of additional biological entities [17] and thermodynamically consistent formulations across multiple scales. In cardiology, computer models have become widely employed [18], with atrial arrhythmias standing out as a particularly active area for research, translation and clinical application, as reviewed recently [19].

M&S provides a highly controlled environment, facilitating the identification of cause-and-effect relationships. Confounding factors, often problematic to control or account for in wet lab settings (e.g. crosstalk between genetic and environmental effects), are more easily manageable *in silico*. Computational approaches demonstrate scalability by design, through parallelization during execution of *in silico* experiments. Experimental design and set-up, as well as the analysis of results represent the primary bottlenecks. An additional benefit of *in silico* research is the absence of inherent variability, obviating the need for repeated experiments. However, when explicit consideration of variability and uncertainty quantification are desired, multiple runs become imperative. Computational approaches prove resource-efficient on multiple fronts by minimizing human effort, reducing the burden on animals and the environment, as well as lowering financial and ethical costs.

As a concrete example, figure 2 depicts a widely used multi-scale modelling framework in cardiac electrophysiology. Beginning at the smallest scale with single ion channels, their kinetics is described using ordinary differential equations (ODE), accounting for factors like ion concentrations and transmembrane voltage ( $V_m$ ) (figure 2A). These ion current models can incorporate effects of genetic mutations, drug effects or altered experimental conditions. Moving to the cell level (figure 2B), electrophysiological models consider the various ion channels present in cardiac cell membranes. Represented by a system of coupled ODE, these models yield action potentials and can be adjusted to reflect different cell states, for example during disease-induced remodelling. In simulation studies, myocyte models are frequently emphasized. However, it is essential






**Figure 2.** Hierarchy of multi-scale cardiac electrophysiology models ranging from ion channels (A) via integrated cell (B) and tissue level models (C) to the body surface and electrocardiogram (D). The simulation system allows one to investigate what-if scenarios by changing the input parameters of the model (top row) and analysing the effect on simulation outputs on numerous scales (bottom row) in comparison with wet lab and clinical data. Adapted with permission from [20].

to recognize that the heart contains more non-myocytes (such as fibroblasts and macrophages) than cardiomyocytes. Models also exist for most of these non-myocyte cell types [21–23]. As excitation propagates through cardiac tissue, spatio-temporal changes in  $V_m$  occur (figure 2C). This coupling can be mathematically represented using reaction–diffusion systems with partial differential equations. This approach allows one to simulate activation wavefront propagation and to integrate factors like anatomical variability or fibrosis in personalized models. Local differences in  $V_m$  generate currents that create an electric field, described by Poisson’s equation. This field extends to the body surface, enabling the acquisition of virtual electrocardiograms (ECG) (figure 2D). Throughout these scales, model parameters can be adapted, for example to represent diseases, to create digital twins for individual patients or digital chimeras representing a likely virtual patient sample from a specific population or to simulate therapeutic interventions (figure 2 top row). Model outputs can be evaluated on all represented biological integration levels (figure 2 bottom row), and also be compared with wet lab and clinical data.

## (b) Digital twin approaches

A digital twin is a personalized computational model of an individual patient, mimicking various aspects of their structure and function. More generally, this approach can also be a digital representation of a technical object (e.g. a cable car shuttling between the village and the mountaintop, or certain components of it) [24]. Though often applied for decision support in critical time steps, digital twins, in general, are dynamically updated throughout their life cycle from the physical twin (figure 3). If such continuous, bidirectional exchange of information between the physical




**Figure 3.** Digital twin workflow. A baseline model builds the basis for the digital twin. Often, it is a bottom-up mechanistic model, informed by biophysical first principles and population-level knowledge. Anatomical and functional personalization are performed based on individual patient measurements (e.g. computed tomography or magnetic resonance imaging for anatomical twinning and ECG for functional twinning). The parametrized digital twin can then be used in computational simulations to make predictions regarding personal risk or support decisions regarding optimal therapy for personalized medicine. The digital twin should be updated continuously when new measurements are available and refined by comparing predictions with real-world outcomes. Adapted with permission from [25].

and the digital twin is not implemented, the terms ‘digital shadow’ or ‘digital snapshot’ have been proposed. Currently often focused on a specific organ, the geometric representation of a personalized computational model is derived from imaging data of the patient’s unique anatomy, which in itself often encodes diagnostic information [26,27]. By adjusting and optimizing functional model parameters based on measured clinical data, the model aims to capture the physiology of the patient’s organ or of multiple organs *in silico*. While more and more comprehensive models and personalization strategies become available, models will by definition always be a simplification of reality. The law of parsimony, also known as Occam’s razor, recommends searching for explanations constructed with the smallest possible set of elements. Figure 4A illustrates these aspects of anatomical and functional twinning.

Digital twins are used for individual risk prediction, decision support and therapy planning [12,25,28]. For example, different options for interventions can be evaluated *in silico* before deciding on the approach to be applied to a patient, in keeping with the personalized medicine vision (figure 4B). While digital twins have proven valuable across diverse medical applications, challenges remain, particularly in automated and robust generation of personalized computer models using clinical data. Addressing these will be crucial for the application of digital twins in broader clinical practice.

### (c) *In silico* clinical trials

*In silico* clinical trials use computational M&S for evaluating the safety and/or efficacy of a medical procedure or product, including drugs and devices [29]. *In silico* clinical trials are a novel and potentially disruptive methodology that can be applied to a multitude of contexts of use including reduction, refinement and replacement of *in vitro*, animal and human experiments [30]. Similar to laboratory experiments and conventional clinical trials, the specific context of use, i.e., ‘the specific



**Figure 4.** Computational M&S approaches. Representing an individual as well as possible with a computational digital twin model requires both anatomical and functional personalization (A). Once a digital twin is established, different interventions can be evaluated *in silico*, for example to support precision medicine (B). If anatomical and functional envelopes are continuous and limited to biologically relevant ranges, arbitrary numbers of new virtual subjects (digital chimeras) can be sampled from this space, representative of a population but not of a specific individual in this population (C). With a whole cohort of digital twins, digital chimeras, or a mix thereof *in silico* clinical trials can be conducted, evaluating the effects of specific interventions consistently applied to the entire virtual study population (D). Figure inspired by Zeike A. Taylor, University of Leeds.

role and scope of the computational model used to address the question of interest' [31], needs to be clearly defined *a priori* [32]. Encouragingly, evidence generated through M&S can be used now during the regulatory qualification process [33–35].

*In silico* clinical trials can be based on a sizeable cohort of digital twin models [36] but creating them at scale is non-trivial, both in terms of effort and data availability. An attractive alternative is the use of methods that allow one to create 'new' virtual individuals—digital chimeras (figure 4C). These are not a digital replica of a specific patient but rather represent properties of a population well in a statistical sense. For the anatomical dimension, statistical shape models are frequently used to draw samples from a continuous space that matches the statistical distribution of the samples that were used to build the statistical shape model [37,38]. For the functional dimension, populations of models can be built from bounded, high-dimensional parameter spaces, for example with Latin hypercube sampling [39], aiming to match empirically observed distributions of simulation output characteristics [40,41].

Once the *in silico* study cohort is established, each virtual participant (either chimera or twin) is subjected to a number of predefined interventions (figure 4D). In contrast to biological participants, multiple interventions can be tested in the same *in silico* individual, starting from the exact

same baseline conditions, potentially yielding more meaningful control and reference data than would be possible in wet lab and clinical settings.

#### (d) Machine learning enabled by M&S

Machine learning, a subset of artificial intelligence (AI), emulates human learning processes by leveraging data, algorithms and statistical models to make predictions without explicit instructions. In medicine, machine learning algorithms now rival or even surpass human capabilities in certain tasks, especially in fields like medical imaging [42] and cardiac electrophysiology [43,44]. Intriguing recent use of AI-enabled ECG processing includes the prediction of biological sex [45], time to death [46], presence of undocumented intermittent atrial fibrillation during sinus rhythm [47], and identification of individuals based on their ECG fingerprint [48].

Despite the apparent abundance of data, machine learning for biomedicine faces a number of challenges including the ‘big data but small data’ paradox. Root causes for this issue are that in practice data are not readily available for legal, ethical or technical reasons (or misconceptions [49]), and that data are not sufficiently standardized or curated [50]. Ground truth datasets with ample size and high-quality labels are frequently absent. Additionally, biased and unbalanced datasets pose questions about capturing relevant data ranges densely enough and about ensuring fairness in the developed machine learning algorithms [51–53].

To enhance machine learning applications in biomedical settings, several potential solutions are being explored: unsupervised or semi-supervised learning to improve data annotation, data augmentation techniques to expand datasets, automation of dataset linkage (learning relations rather than manually defining them), federated learning across multiple institutions without the need of data sharing [54], encouraging and facilitating data donation and incentivizing publication of FAIR (findable, accessible, interoperable, reusable) and ideally open data, metadata and code [55,56]. Computational M&S is one of the fields with vast potential to tackle the above-mentioned problems by integrating machine learning and multi-scale modelling to leverage synergies between the two approaches [11,57–59]. A combination of machine learning and M&S methods can allow for better phenotyping and stratification of diseases [59]. Furthermore, many of the legal and ethical issues do not apply to synthetic data, and ground truth annotations can be assigned with very high certainty in most M&S approaches. Using appropriate sampling schemes, the balance of classes (e.g. healthy controls and different disease subtypes) and parameters (e.g. age, sex, obesity) can be controlled. In multi-scale models, data augmentation can be lifted to higher levels by enabling mix and match, for example combining  $N$  heart models with  $M$  torso models, resulting in  $N \times M$  permutations. In such approaches, covariances should be accounted for [38]. *In silico* generated data can serve as training data (either purely synthetic [60,61] or hybrid [62,63] when combined with real-world recordings) for developing machine learning algorithms that are then evaluated on real-world signals. In keeping with this, many open benchmark datasets with well-defined ground truth are synthetic.

In spite of its huge potential, the use of M&S for generating machine learning training data also introduces specific challenges. One needs to ensure model fidelity (i.e. accurately reflecting real-world scenarios) through rigorous and use case-specific validation [64]. Difficulties include the identification of an upper limit of predictive error for any relevant real-world input data beyond the calculation of the predictive accuracy over a finite number of observed values, as well as the ‘plausibility trap’: model outputs (mechanistic or data-driven) that match observed biological behaviour are not necessarily a proof for having found (explicitly or implicitly) the underlying causal link [65]. Potential domain gaps between simulated and real-world data can also be due to model oversimplifications. As an example, if the model does not include the signal acquisition process, the simulated data will not contain measurement noise. To be suitable for training a machine learning algorithm that is hoped to perform well on noisy real-world data, these synthetic data will need to be artificially ‘corrupted’ with realistic noise [61]. Another aspect is that simulated data are not guaranteed to cover the relevant variability by default. As an example, one

needs to consider the diversity in the dataset used to generate a statistical shape model when aiming to represent a diverse population well. Any machine learning approach will only be as good as the training data, which causes problems when uncommon cases are under-represented. In addition to cases not adequately represented in the training set, there can also be ‘silent variables’ that do not significantly affect the specific quantity of interest and thus limit the generalization capacity of the model. For example, the variable age might not be needed to predict myocardial infarction risk in a given dataset used to develop the machine learning model. However, for more general out-of-sample applications, the predictor might perform poorly when not taking age into account.

Despite examples of the remarkable classification power of purely data-driven approaches, we believe that knowledge adds value as a way to understand the true nature of the problem rather than being left with a fragmented landscape of bits of insight. While the field of explainable artificial intelligence (xAI) tries to address this shortcoming, current approaches only provide insight into which input data are essential for the decision, rather than why they are (in many cases). Machine learning that is constrained by the laws of physics or mechanistic models of biological function can be a way of synergistically combining data-driven and mechanistic approaches.

One promising method to achieve this combination is the use of physics-informed neural networks and other methods of scientific machine learning [66] that offer advantages regarding consistency with physics, data efficiency, extrapolation capacity and applicability to inverse problems. This emerging class of tools has already been used for a wide range of applications in cardiovascular M&S [67–70]. Another way of merging mechanistic M&S with data-driven approaches is the use of statistical emulators and neural operators that reduce the computational effort when calculating specific quantities of interest and thus allow for parameter identification combined with uncertainty quantification and sensitivity analysis including higher order interdependencies [71–76].

### 3. Tools and ecosystems

The monumental task of constructing the human Physiome can only be achieved by a collaborative effort involving the integration of numerous modules in open and interoperable ecosystems. These modules comprise, for example, single-organ and single-physics models, data repositories, as well as pre- and post-processing pipelines. Key prerequisites for enabling them to work together include establishing standards that aid interoperability and sharing data, metadata and code. As these principles align naturally with the notion of Open Science, its rise is no surprise. This rise is driven by the recognition that collaboration, transparency, and shared resources are essential for the progress of modern day research and development. Open Science fosters reproducibility, increases efficiency and reduces redundant efforts.

Physiologically detailed computational M&S heavily relies on experimental data for the design, parametrization and validation of models. Adherence to the FAIR principles is crucial for getting closer to the realization of the Physiome vision and ideally data and metadata should both also be open [50]. To facilitate implementation, ‘Ten Simple Rules for FAIR Sharing of Experimental and Clinical Data with the Modeling Community’ [77] and the CURE principles (credible, understandable, reproducible and extensible) [78] were formulated. Additionally, the modelling community often gives back results of anatomical model building [79,80] and simulation studies [40] and has demonstrated the benefits associated with wide use, especially when using standardized reference frames [81–83]. Subsequent studies were enabled through sharing these models, the original authors get credit from citing the data publication, and society benefits from the new insights that might otherwise not have been obtained at all or at a higher cost. Despite commendable efforts to reform research assessment, like DORA [84] and CoARA [85], the lack of proper incentive and recognition systems for sharing models, data, metadata and code remains a substantial hindrance to the implementation of Open Science in general, and the FAIR principles in particular.



Besides data and metadata, software is crucial for M&S. The FAIR principles for research software (FAIR4RS) have only recently been formulated (in 2022 [56]), even though the essential role of software has long been acknowledged [86]. Thriving M&S ecosystems can emerge based on FAIR research software [87–89], workflows [81,90,91] and collaborative development environments [92,93].

For data and code, standards are an essential requirement, enabling interoperability and modularization [94,95]. Examples include CellML [96], SBML [97], FieldML [98] and the SPARC data structure [99], as well as numerous domain-specific markup languages catering for specific research domains [100,101]. Often building on community conventions, international standards were established including ISO TS 9491:2023 (Recommendations and requirements for predictive computational models in personalized medicine research), ISO 20691:2022 (Requirements for data formatting and description in the life sciences), ISO 23494 (Provenance information model for biological material and data) and ASME V&V40 (Assessing credibility of computational modelling through verification and validation: application to medical devices). A common language and clear interfaces can then enable large collaborative efforts like the 12 LABOURS Digital Twin Platform [102], or decentralized portfolio approaches as envisioned in the European Virtual Human Twin Manifesto [103] and roadmap [104], as critically discussed in a recent review [105].

Besides technical harmonization, community building has been a driver for sustained impact in the last decades. The VPH community, coordinated by the VPH Institute [5], the Computational Modeling in Biology Network (COMBINE) [94] or software-centred communities [89,106] are just a few examples. The International Union of Physiological Sciences (IUPS) is taking a leading role in this field by driving the Physiome project, building and operating the Physiome model repository [107], organizing symposia and co-publishing the *Physiome* journal.

In conclusion, tools and people are essential for thriving and sustainable *in silico* ecosystems. While tool and data sharing can be tackled by the community through technical means, ill-developed professional recognition mechanisms and the frequent disconnect between project funding cycles, which are limited by definition on the one side, and ambitions and expectations for sustained software development and support impact on the other side, form challenges to which new solutions must be found by academia, industry, regulators and politics. Both systems and communities need support to remain functional and valuable, as already identified in the 1970s in Lehman's laws of software evolution [108]. Educational structures are also rarely aligned well enough with the needs of interdisciplinary research in general, and the emergence of disruptive technologies (such as AI-based M&S) in particular. When training the next generations of scientists, too few programmes aim at developing a truly diverse set of skills covering wet lab, *in silico* and clinical content [109].

## 4. Cardiology applications

Cardiology stands out as a field with particularly active and successful M&S activities, as reviewed in detail elsewhere [19,110,111]. Here, we focus on select twenty-first century examples to provide the interested reader with starting points for further exploration of cardiac M&S. Through these spotlights, we aim to showcase the versatility and impact of computational modelling in addressing complex problems across different facets of cardiology. The examples not only underscore the achievements of M&S in this field but hopefully also serve as inspirations for further exploration and innovation within the broader landscape of cardiovascular research.

The cardiac 'function' with the longest history of computational M&S is electrophysiology. Soon after the establishment of the seminal Hodgkin–Huxley model for the electrophysiology of neurons, Noble adapted it to Purkinje cells in the heart (in 1962 [112]). Presently, models implementing the concepts introduced in figure 2 are largely rooted in those early works and build on their principles. To strike a balance between physiological detail and computational cost, models can be deliberately reduced or embedded in model hierarchies with increasing complexity [113]. Cardiac electrophysiology models find routine application in arrhythmia [110] and ischaemia

research [20,114], for ECG simulations [115], and they hold promise for personalizing ablation therapy [116] as well as for accelerating drug development [117].

Ultimately, the heart's main function is that of a mechanical pump, which has also been replicated *in silico* [118] including material properties [119] and growth [120]. Electrical and mechanical functions are coupled bidirectionally through excitation contraction coupling and mechano-electric feedback [121]. This interplay has been analysed in detail in several simulation studies using electro-mechanically coupled models [122–125]. Blood flow through the heart and the circulatory system can be studied *in silico* using computational fluid dynamics and fluid structure interaction models [126–129].

Since the turn of the millennium, M&S have been used for numerous cardiological contexts of use [30]. In mechanistic and basic research, simulation studies helped, for example to better understand electrogram [130] and ECG genesis [131–133], disease mechanisms [134,135] as well as pharmacological modes of action [136–138]. The CiPA initiative was launched in 2013 to engineer an assay for assessment of the proarrhythmic potential of new drugs with improved specificity compared with the hERG assay plus a thorough QT study [139]. This example—steered by international regulators, industry, academics and non-profit organizations—shows how support by key stakeholders including regulators can accelerate and enhance impact [140]. The latest version of the ICH Guideline ‘Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential’ (ICH E14/S7B) explicitly encourages the use of *in silico* models to integrate experimental ion channel data for clinical and preclinical research and development.

A wide range of digital twin approaches has been proposed for personalized ablation therapy [122,141–147] and the first prospective clinical trials involving modelling-derived predictions report favourable results [148,149].

Cardiac *in silico* clinical trials have been reviewed elsewhere [150] and include virtual ablation studies [151–153], culminating in a holistic benchmark setting for mapping-guided ablation, covering the full process from catheter positioning and deformation via signal acquisition, filtering and processing to the selection of ablation sites [154]. The well-controlled *in silico* setting has been used as a complementary approach to integrate and consolidate clinical trials [155] and for systematic evaluation of newly developed or refined medical devices [156] and algorithms [157,158]. In the field of cardiac pharmacology, *in silico* methods support the evaluation of drug efficacy and safety in sizeable cohorts of several hundred virtual patients, often following the digital chimera approach described in figure 4C [159–161]. Similar approaches have also been used to study haemodynamics [162].

Several of the machine learning breakthroughs seen in recent years in the cardiology field [44] were enabled by M&S, which highlights the potential for synergy between data-driven and mechanistic models. The possibility of augmenting datasets on specific anatomical and functional levels (figure 4) was used, for example, for training classifiers to predict the acute success of pulmonary vein isolation as a treatment of atrial fibrillation [62], for distinguishing different types of atrial flutter [60], and for localizing the origin of ventricular ectopic beats [61,163]. All these examples relied on multi-scale simulation of cardiac electrophysiology ranging up to the ECG as provided in the open MedalCare-XL dataset [40], comprising 16 900 healthy and pathological synthetic 12-lead ECG recordings. Better control of the distribution of samples across classes (e.g. balanced size of control and disease cohorts) helped to improve the diagnosis of fibrotic atrial myopathy [164], left atrial enlargement [165], and electrolyte imbalance [52]. In some cases, the synthetic training data were augmented with a small number of clinical recordings, resulting in a hybrid training dataset [60,63,166,167].

## 5. Outlook

As M&S continue to develop at the intersection of computational advances and biomedical exploration, the outlook for the future is exciting. The rapid evolution of M&S techniques we have witnessed since the turn of the millennium, coupled with the continuing progress in machine

learning and Open Science practices, has started to propel the field to new frontiers. In the forthcoming years, the application of computational approaches in cardiology and beyond is poised to deepen, addressing increasingly complex questions with high precision. M&S can serve as a catalyst for the advancement of digitally controlled wet labs and contribute to tightly linked and fast iterations between wet lab experiments, big data analysis, conceptual hypotheses, mechanistic models, *in silico* plausibility testing and comprehensive evaluation, leading to new hypotheses that can be experimentally validated and to refined experimental designs partially exploiting automated AI-driven laboratories for compound synthesis. This has heralded a revolution in drug design and testing, reducing time and cost [168]. Robust standards, data and code sharing, curation and incentivization are required to stay on a dynamic trajectory of M&S. This section highlights essential challenges in three application areas that need to be addressed to yield innovations that will shape the future landscape of M&S in biomedical research.

### (a) Frontiers for computational models

Concerning model formulations, current challenges include the requirement to improve multi-physics models. Existing electromechanical models [122,124,169] and fluid mechanical models [126] are on the way of being extended to include perfusion [170], growth [171] and metabolism. Maintaining biophysical and energetic consistency not only across scales but also across ‘functions’ is not trivial [172]. This becomes relevant as well when extending models towards even more microscopic scales like the extracellular-membrane-intracellular model for electrophysiology [173,174] potentially also including multiple cell types and extracellular structures. Another continuous issue is model validation for additional contexts of use [175–177], often complicated by scarce experimental data or limited access, also concerning control data from internal organs in humans. Continuing experimental discoveries including non-canonical interactions of signals, cells and organs will further enhance the need for and return from M&S. 10 years ago, the concept of immunocardiology did not exist yet and even the intracardiac nervous system turns out to be much more complex than traditionally assumed.

The breadth of methods applied in the field of M&S poses ever-growing requirements on the training of researchers. The body of relevant knowledge continues to grow in all disciplines involved and skills ranging from finite element analysis via machine learning to physiology and medicine are essential to use the full potential of *in silico* methodologies. Stringent time limits in many phases of training, ranging from undergraduate studies to postdocs, can amplify the problem. As a single individual can hardly be trained in all relevant fields, improved communication across disciplines may be the only viable and attractive solution. It will be interesting to see whether larger labs or intensified collaboration will be the better way, but we need to learn and practise how to communicate across disciplines: translation needs translators!

The advent of generative AI and foundation models including large language models offers unprecedented potential for even tighter integration of data-driven and mechanistic models and may further blur the boundaries between them. To capitalize on this potential, tools and interfaces for bidirectional data exchange between those village and mountaintop views will be required, combined with novel concepts for validation of model predictions.

### (b) Frontiers for advancing digital twins

When using M&S to facilitate precision medicine through digital twins, personalization of generic baseline models is a major task. Estimating model parameters from clinical and/or experimental measurements often involves solving inverse problems [105]. This can usually only be achieved with limited temporal and spatial resolution and remaining uncertainty [119,178–185]. When integrating and assimilating multiple data sources, models can become over-constrained so that data and model fidelity need to be balanced [186], a process in which machine learning approaches like physics-informed neural networks can be valuable tools [68]. How input parameter uncertainty

and variability influence simulation outputs after being propagated through a model calls for dedicated analyses [73,187–192], for example using uncertainty quantification tools [193]. Large numbers of simulations and clinical time frames may require accelerated models [194].

While the concept of a systematic digital representation of human pathophysiology, a comprehensive digital twin, has been under consideration for many years, existing research primarily focuses on specialized patient-specific models predicting specific clinical entities, often at single points in time and/or limited to single organs [195]. The development of comprehensive digital twins faces multifaceted challenges including scientific, technical, ethical, legal and cultural aspects, as outlined in the Virtual Human Twin Manifesto [103]. A recent draft for a Virtual Human Twin roadmap [104] details specific actions, including the development of a data repository, intellectual property management, incentives, regulatory clarity, clinical evidence generation and universal access to digital twin technology in healthcare. Despite the efforts for more and more comprehensive models, we should not forget the value of the simplification and abstraction that models offer, which can be advantageous for enabling mechanistic insight in knowledge-generating research.

### (c) Frontiers for advancing *in silico* clinical trials

*In silico* clinical trials rely on big cohorts, such as those included in the UK Biobank [196]. In practice, scaling up digital twin model generation (figure 4A) to this range remains challenging [28]. Thus, methods to digitally sample specific aspects of the models from underlying biological distributions are attractive to better control variability using a limited set of real-world samples. While digital chimeras (figure 4C) as the individuals in synthetically derived populations of models/*in silico* cohorts (figure 4D) can be informed by parameter ranges [39] or statistical shape models [79,197], identifying the underlying probability distribution for a target population without bias remains non-trivial [51,198]. This is particularly challenging for high-dimensional parameter spaces with non-obvious interrelations of parameters, which need to be captured to constitute physiologically relevant virtual subjects [38]. If balanced data are not readily available, such as can be the case for (often under-reported) sex-specific or ethnicity-related differences [7], computational M&S can help to mitigate imbalances [199].

## 6. Conclusion

The evolution of computational modelling of biological systems since the turn of the millennium has been nothing short of remarkable, ushering in mature applications across basic and clinical research. Equally remarkable is how much the visions for societal benefit, presented at the turn of the millennium [1], still hold today. While predictions in some fields might seem pragmatically optimistic when looking back, we also started seeing results of M&S adding value in many areas of basic and applied research. After the historical debate on ‘reductionism & integrationism’ has all but subdued [200], a fresh dichotomy between mechanistic and data-driven modelling takes centre stage. Regardless of whether one sees the associated developments as challenges or opportunities, the dynamics of recent progress suggests that we may increasingly be able to combine the mountain and village views of research, much like computational technology powering virtual meetings enabled us to be in two places at the same time nowadays. Shifting focus from universal models to individualized representations including digital twins and digital chimeras for *in silico* basic research and clinical trials opens up exciting new avenues for future exploitation. Tackling the challenge of disease-specific models that take into account demographic information, intra- and inter-individual variability, uncertainty quantification and data standardization necessitate open collaboration, concerted community efforts and the use of reliable tools and standards. The tightly controlled environment offered by *in silico* methods has become integrated into physiological and medical research, including multi-physics modelling, multi-scale studies, virtual cohort simulations and machine learning. The

synergy between mechanistic and data-driven modelling may become a powerful force to drive the next wave of AI applications, particularly where the AI algorithms can incorporate constraints from both physiological datasets and from multi-scale bond graph models that conserve mass, charge and energy [172,201]. This holds the promise of reshaping our understanding of physiology and disease mechanisms, fostering the generation and evaluation of innovative hypotheses and ultimately contributing to the ongoing progress of preventive, diagnostic and therapeutic approaches.

**Data accessibility.** This article has no additional data.

**Declaration of AI use.** During the preparation of this work, the authors used ChatGPT for drafting and improving linguistic quality of the text. After using this service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.

**Authors' contributions.** A.L.: conceptualization, visualization, writing—original draft, writing—review and editing; P.J.H.: conceptualization, writing—review and editing; P.K.: conceptualization, writing—review and editing.

All authors gave final approval for publication and agreed to be held accountable for the work performed therein.

**Conflict of interest declaration.** We declare we have no competing interests.

**Funding.** This work was supported by the Leibniz ScienceCampus 'Digital Transformation of Research' with funds from the programme 'Strategic Networking in the Leibniz Association', as well as the German Research Foundation Collaborative Research Centre SFB1425 (no. 422681845) and the NZ Government '12 Labours' MBIE grant. This work was supported by the MICROCARD-2 project (project ID 101172576). The project is supported by the EuroHPC Joint Undertaking and its members (including top-up funding by ANR, BMBF, and Ministero dello sviluppo economico). Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or EuroHPC. Neither the European Union nor EuroHPC can be held responsible for them.

**Acknowledgements.** The authors acknowledge helpful feedback on the manuscript by Carmen Martínez Antón, Joshua Steyer and Patricia Martínez Díaz.

## References

1. Kohl P, Noble D, Winslow RL, Hunter PJ. 2000 Computational modelling of biological systems: tools and visions. *Phil. Trans. R. Soc. Lond. A* **358**, 579–610. (doi:10.1098/rsta.2000.0547)
2. Hunter PJ, Borg TK. 2003 Integration from proteins to organs: the physiome project. *Nat. Rev. Mol. Cell Biol.* **4**, 237–243. (doi:10.1038/nrm1054)
3. Hunter P *et al.* 2010 A vision and strategy for the virtual physiological human in 2010 and beyond. *Philos. Trans. A Math. Phys. Eng. Sci.* **368**, 2595–2614. (doi:10.1098/rsta.2010.0048)
4. Bassingthwaite J, Hunter P, Noble D. 2009 The cardiac physiome: perspectives for the future. *Exp. Physiol.* **94**, 597–605. (doi:10.1113/expphysiol.2008.044099)
5. Hunter P *et al.* 2013 A vision and strategy for the virtual physiological human: 2012 update. *Interface Focus* **3**, 20130004. (doi:10.1098/rsfs.2013.0004)
6. Morotti S *et al.* 2021 Quantitative cross-species translators of cardiac myocyte electrophysiology: model training, experimental validation, and applications. *Sci. Adv.* **7**, eabg0927. (doi:10.1126/sciadv.abg0927)
7. St Pierre SR, Peirlinck M, Kuhl E. 2022 Sex matters: a comprehensive comparison of female and male hearts. *Front. Physiol.* **13**, 831179. (doi:10.3389/fphys.2022.831179)
8. Siontis KC, Noseworthy PA, Attia ZI, Friedman PA. 2021 Artificial intelligence-enhanced electrocardiography in cardiovascular disease management. *Nat. Rev. Cardiol.* **18**, 465–478. (doi:10.1038/s41569-020-00503-2)
9. Feeny AK *et al.* 2020 Artificial intelligence and machine learning in arrhythmias and cardiac electrophysiology. *Circ. Arrhythm. Electrophysiol.* **13**, e007952. (doi:10.1161/CIRCEP.119.007952)



10. Attia ZI, Harmon DM, Behr ER, Friedman PA. 2021 Application of artificial intelligence to the electrocardiogram. *Eur. Heart J.* **42**, 4717–4730. (doi:10.1093/eurheartj/ehab649)
11. Nagarajan VD, Lee SL, Robertus JL, Nienaber CA, Trayanova NA, Ernst S. 2021 Artificial intelligence in the diagnosis and management of arrhythmias. *Eur. Heart J.* **42**, 3904–3916. (doi:10.1093/eurheartj/ehab544)
12. Corral-Acero J *et al.* 2020 The ‘Digital Twin’ to enable the vision of precision cardiology. *Eur. Heart J.* **41**, 4556–4564. (doi:10.1093/eurheartj/ehaa159)
13. Sun Z, Bai R, Bai Z. 2023 The application of simulation methods during the COVID-19 pandemic: a scoping review. *J. Biomed. Informatics* **148**, 104543. (doi:10.1016/j.jbi.2023.104543)
14. Eurostat. 2023 Mortality and life expectancy statistics. See [https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Mortality\\_and\\_life\\_expectancy\\_statistics](https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Mortality_and_life_expectancy_statistics) (accessed 14 January 2024).
15. Remme CA, Heijman J, Gomez AM, Zaza A, Odening KE. 2023 25 years of basic and translational science in EP Europace: novel insights into arrhythmia mechanisms and therapeutic strategies. *Europace* **25**, euad210. (doi:10.1093/europace/euad210)
16. Gerach T, Appel S, Wilczek J, Golba KS, Jadczyk T, Loewe A. 2022 Dyssynchronous left ventricular activation is insufficient for the breakdown of wringing rotation. *Front. Physiol.* **13**, 838038. (doi:10.3389/fphys.2022.838038)
17. Tveito A, Mardal K, Rognes M (eds). 2021 *Modeling excitable tissue: the EMI framework*. Cham, Switzerland: Springer International Publishing. (doi:10.1007/978-3-030-61157-6)
18. Niederer SA, Lumens J, Trayanova NA. 2019 Computational models in cardiology. *Nat. Rev. Cardiol.* **16**, 100–111. (doi:10.1038/s41569-018-0104-y)
19. Heijman J, Sutanto H, Crijns HJGM, Nattel S, Trayanova NA. 2021 Computational models of atrial fibrillation: achievements, challenges, and perspectives for improving clinical care. *Cardiovasc. Res.* **117**, 1682–1699. (doi:10.1093/cvr/cvab138)
20. Loewe A, Wülfers EM, Seemann G. 2018 Cardiac ischemia-insights from computational models. *Herzschrittmacherther. Elektrophysiol.* **29**, 48–56. (doi:10.1007/s00399-017-0539-6)
21. Xie Y, Garfinkel A, Camelliti P, Kohl P, Weiss JN, Qu Z. 2009 Effects of fibroblast-myocyte coupling on cardiac conduction and vulnerability to reentry: a computational study. *Heart Rhythm* **6**, 1641–1649. (doi:10.1016/j.hrthm.2009.08.003)
22. Simon-Chica A, Fernández MC, Wülfers EM, Lother A, Hilgendorf I, Seemann G, Ravens U, Kohl P, Schneider-Warme F. 2021 Novel insights into the electrophysiology of murine cardiac macrophages: relevance of voltage-gated potassium channels. *Cardiovasc. Res.* **118**, 798–813. (doi:10.1093/cvr/cvab126)
23. Seemann G, Loewe A, Wülfers EM. 2017 Effects of fibroblasts coupling on the electrophysiology of cardiomyocytes from different regions of the human atrium: a simulation study. In *Computing in Cardiology*, vol. 44. (doi:10.22489/CinC.2017.380-451)
24. Committee ADEL. 2020 Digital twin: definition & value. In *An AIAA and AIA position paper, American Institute of Aeronautics and Astronautics (AIAA) and Aerospace Industries Association (AIA)*. Arlington, VA: AIA.
25. Loewe A, Martínez Díaz P, Nagel C, Sánchez J. 2022 Cardiac digital twin modeling. In *Innovative treatment strategies for clinical electrophysiology* (eds T Jadczyk, A Loewe, G Caluori, KS Golba), pp. 111–134. Singapore: Springer. (doi:10.1007/978-981-19-6649-1\_7)
26. Govil S, Mauger C, Hegde S, Occleshaw CJ, Yu X, Perry JC, Young AA, Omens JH, McCulloch AD. 2023 Biventricular shape modes discriminate pulmonary valve replacement in tetralogy of fallot better than imaging indices. *Sci. Rep.* **13**, 2335. (doi:10.1038/s41598-023-28358-w)
27. Jia S, Nivet H, Harrison J, Pennec X, Camaioni C, Jaïs P, Cochet H, Sermesant M. 2021 Left atrial shape is independent predictor of arrhythmia recurrence after catheter ablation for atrial fibrillation: a shape statistics study. *Heart Rhythm O2* **2**, 622–632. (doi:10.1016/j.hroo.2021.10.013)
28. Niederer SA, Sacks MS, Girolami M, Willcox K. 2021 Scaling digital twins from the artisanal to the industrial. *Nat. Comput. Sci.* **1**, 313–320. (doi:10.1038/s43588-021-00072-5)
29. Viceconti M, Henney A, Morley-Fletcher E. 2016 *In silico* clinical trials: how computer simulation will transform the biomedical industry. *Int. J. Clin. Trials* **3**, 37. (doi:10.18203/2349-3259.ijct20161408)
30. Viceconti M *et al.* 2021 Possible contexts of use for *in silico* trials methodologies: a consensus-based review. *IEEE J. Biomed. Health Informatics* **25**, 3977–3982. (doi:10.1109/jbhi.2021.3090469)

31. V&V40 A. 2018 *Assessing credibility of computational modeling through verification and validation: application to medical devices*. New York, NY: The American Society of Mechanical Engineers.
32. Viceconti M, Emili L (eds). 2024 *Toward good simulation practice - best practices for the use of computational modelling and simulation in the regulatory process of biomedical products*. Cham, Switzerland: Springer International Publishing. (doi:10.1007/978-3-031-48284-7)
33. Modeling & simulation working group of the senior science council of the FDA. 2022 Successes and opportunities in modeling & simulation for FDA. See <https://www.fda.gov/media/163156/download>.
34. Frangi A *et al.* 2023 *Unlocking the power of computational modelling and simulation across the product lifecycle in life sciences: a UK landscape report*. (doi:10.5281/zenodo.8325274)
35. European Medicines Agency. 2025 *Concept paper on the development of a Guideline on assessment and reporting of mechanistic models used in the context of model informed drug development*. See <https://www.ema.europa.eu/en/guideline-assessment-reporting-mechanistic-models-used-context-model-informed-drug-development> (accessed 10 March 2025).
36. Sarrami-Foroushani A, Lassila T, MacRaid M, Asquith J, Roes KCB, Byrne JV, Frangi AF. 2021 In-silico trial of intracranial flow diverters replicates and expands insights from conventional clinical trials. *Nat. Commun.* **12**, 3861. (doi:10.1038/s41467-021-23998-w)
37. Ambellan F, Lamecker H, von Tycowicz C, Zachow S. 2019 Statistical shape models: understanding and mastering variation in anatomy. In *Advances in experimental medicine and biology* (ed. PM Rea), pp. 67–84, vol. **1156**. Cham, Switzerland: Springer International Publishing. (doi:10.1007/978-3-030-19385-0\_5)
38. Dou H, Virtanen S, Ravikumar N, Frangi AF. 2024 A generative shape compositional framework to synthesize populations of virtual chimeras. *IEEE Trans. Neural Netw. Learn. Syst.* **36**, 1–15. (doi:10.1109/TNNLS.2024.3374121)
39. Britton OJ, Bueno-Orovio A, Van Ammel K, Lu HR, Towart R, Gallacher DJ, Rodriguez B. 2013 Experimentally calibrated population of models predicts and explains intersubject variability in cardiac cellular electrophysiology. *Proc. Natl Acad. Sci. USA* **110**, E2098–105. (doi:10.1073/pnas.1304382110)
40. Gillette K *et al.* 2023 MedaCare-XL: 16,900 healthy and pathological synthetic 12 lead ECGs from electrophysiological simulations. *Sci. Data* **10**, 531. (doi:10.1038/s41597-023-02416-4)
41. Lawson BAJ, Drovandi CC, Cusimano N, Burrage P, Rodriguez B, Burrage K. 2018 Unlocking data sets by calibrating populations of models to data density: a study in atrial electrophysiology. *Sci. Adv.* **4**, e1701676. (doi:10.1126/sciadv.1701676)
42. Sermesant M, Delingette H, Cochet H, Jaïs P, Ayache N. 2021 Applications of artificial intelligence in cardiovascular imaging. *Nat. Rev. Cardiol.* **18**, 600–609. (doi:10.1038/s41569-021-00527-2)
43. Loewe A, Luongo G, Sánchez J. 2022 Machine learning for clinical electrophysiology. In *Innovative treatment strategies for clinical electrophysiology* (eds T Jadczyk, A Loewe, G Caluori, KS Golba). Singapore: Springer. (doi:10.1007/978-981-19-6649-1\_6)
44. Trayanova NA, Popescu DM, Shade JK. 2021 Machine learning in arrhythmia and electrophysiology. *Circ. Res.* **128**, 544–566. (doi:10.1161/circresaha.120.317872)
45. Sau A, Sieliwonczy E, Patlatzoglou K. 2025 Artificial intelligence-enhanced electrocardiography for the identification of a sex-related cardiovascular risk continuum: a retrospective cohort study. *Lancet Digit. Health* **7**, e184–e194. (doi:10.1016/j.landig.2024.12.003)
46. Sau A *et al.* 2025 A comparison of artificial intelligence-enhanced electrocardiography approaches for the prediction of time to mortality using electrocardiogram images. *Eur. Heart J. Digit. Health* **6**, 180–189. (doi:10.1093/ehjdh/ztae090)
47. Noseworthy PA *et al.* 2022 Artificial intelligence-guided screening for atrial fibrillation using electrocardiogram during sinus rhythm: a prospective non-randomised interventional trial. *The Lancet* **400**, 1206–1212. (doi:10.1016/S0140-6736(22)01637-3)
48. Macierzanka K *et al.* 2025 Siamese neural network-enhanced electrocardiography can re-identify anonymized healthcare data. *European Heart J. Digital Health* (doi:10.1093/ehjdh/ztaf011)
49. Gefenas E, Lekstutiene J, Lukaseviciene V, Hartlev M, Mourby M, Cathaoir KÓ. 2022 Controversies between regulations of research ethics and protection of personal data: informed consent at a cross-road. *Med. Health Care. Philos.* **25**, 23–30. (doi:10.1007/s11019-021-10060-1)

50. Steffens S, Schröder K, Krüger M. 2023 The challenges of research data management in cardiovascular science: a DGK and DZHK position paper-executive summary. *Clin. Res. Cardiol.* **113**, 672–679. (doi:10.1007/s00392-023-02303-3)
51. Puyol-Antón E, Ruijsink B, Piechnik SK, Neubauer S, Petersen SE, Razavi R, King AP. 2021 Fairness in cardiac MR image analysis: an investigation of bias due to data imbalance in deep learning based segmentation. In *Medical image computing and computer assisted intervention – MICCAI 2021*, pp. 413–423. Cham, Switzerland: Springer International Publishing. (doi:10.1007/978-3-030-87199-4\_39)
52. Pilia N, Severi S, Raimann JG, Genovesi S, Dössel O, Kotanko P, Corsi C, Loewe A. 2020 Quantification and classification of potassium and calcium disorders with the electrocardiogram: what do clinical studies, modeling, and reconstruction tell us? *APL Bioeng.* **4**, 041501. (doi:10.1063/5.0018504)
53. Jones C, Castro DC, De Sousa Ribeiro F, Oktay O, McCradden M, Glocker B. 2024 A causal perspective on dataset bias in machine learning for medical imaging. *Nat. Mach. Intell.* (doi:10.1038/s42256-024-00797-8)
54. Rieke N, Hancox J, Li W. 2020 The future of digital health with federated learning. *NPJ Digit. Med.* **3**, 119. (doi:10.1038/s41746-020-00323-1)
55. Wilkinson MD *et al.* 2016 The FAIR guiding principles for scientific data management and stewardship. *Sci. Data* **3**, 160018. (doi:10.1038/sdata.2016.18)
56. Chue HongNP, KatzDS, Barker M. 2022 FAIR principles for research software (FAIR4RSPinciples). RDA. (doi:10.15497/RDA00068)
57. Alber M *et al.* 2019 Integrating machine learning and multiscale modeling—perspectives, challenges, and opportunities in the biological, biomedical, and behavioral sciences. *Npj Digit. Med.* **2**, 115. (doi:10.1038/s41746-019-0193-y)
58. McDuff D, Curran T, Kadambi A. 2023 Synthetic data in healthcare. *eprint* (doi:10.48550/arXiv.2304.03243)
59. Lyon A, Mincholé A, Bueno-Orovio A, Rodriguez B. 2019 Improving the clinical understanding of hypertrophic cardiomyopathy by combining patient data, machine learning and computer simulations: a case study. *Morphologie* **103**, 169–179. (doi:10.1016/j.morpho.2019.09.001)
60. Luongo G *et al.* 2022 Machine learning enables non-invasive prediction of atrial fibrillation driver location and acute pulmonary vein ablation success using the 12-lead ECG. *Cardio. Digit. Health J.* **2**, 126–136. (doi:10.1093/europace/euab322)
61. Pilia N, Schuler S, Rees M, Moik G, Potyagaylo D, Dössel O, Loewe A. 2023 Non-invasive localization of the ventricular excitation origin without patient-specific geometries using deep learning. *Artif. Intell. Med.* **143**, 102619. (doi:10.1016/j.artmed.2023.102619)
62. LuongoG *et al.* 2022 Hybrid machine learning to localize atrial flutter substrates using the surface 12-lead ECG. *Europace* **24**, 1186–1194. (doi:10.1093/europace/euab322)
63. Sánchez J, Luongo G, Nothstein M, Unger LA, Saiz J, Trenor B, Luik A, Dössel O, Loewe A. 2021 Using machine learning to characterize atrial fibrotic substrate from intracardiac signals with a hybrid *in silico* and *in vivo* dataset. *Front. Physiol.* **12**, 699291. (doi:10.3389/fphys.2021.699291)
64. Aldieri A, Gamage TPB, Amedeo La Mattina A, Loewe A, Pappalardo F, Viceconti M. 2025 Consensus statement on the credibility assessment of machine learning predictors. *Brief. Bioinformatics* **26**, bbaf100. (doi:10.1093/bib/bbaf100)
65. Quinn TA, Kohl P. 2011 Systems biology of the heart: hype or hope? *Ann. NY. Acad. Sci.* **1245**, 40–43. (doi:10.1111/j.1749-6632.2011.06327.x)
66. Quarteroni A, Gervasio P, Regazzoni F. 2025 Combining physics-based and data-driven models: advancing the frontiers of research with scientific machine learning. *Math. Models Methods Appl. Sci.* 1–167. (doi:10.1142/S0218202525500125)
67. Ruiz Herrera C, Grandits T, Plank G, Perdikaris P, Sahli Costabal F, Pezzuto S. 2022 Physics-informed neural networks to learn cardiac fiber orientation from multiple electroanatomical maps. *Eng. Comput.* **38**, 3957–3973. (doi:10.1007/s00366-022-01709-3)
68. Caforio F, Regazzoni F, Pagani S, Karabelas E, Augustin C, Haase G, Plank G, Quarteroni A. 2025 Physics-informed neural network estimation of material properties in soft tissue nonlinear biomechanical models. *Comput. Mech.* **75**, 487–513. (doi:10.1007/s00466-024-02516-x)

69. Herrero Martin C, Oved A, Chowdhury RA, Ullmann E, Peters NS, Bharath AA, Varela M. 2021 EP-PINNs: cardiac electrophysiology characterisation using physics-informed neural networks. *Front. Cardiovasc. Med.* **8**, 768419. (doi:10.3389/fcvm.2021.768419)
70. Sahli Costabal F, Yang Y, Perdikaris P, Hurtado DE, Kuhl E. 2020 Physics-informed neural networks for cardiac activation mapping. *Front. Phys.* **8**. (doi:10.3389/fphy.2020.00042)
71. Coveney S, Clayton RH. 2018 Fitting two human atrial cell models to experimental data using Bayesian history matching. *Prog. Biophys. Mol. Biol.* **139**, 43–58. (doi:10.1016/j.pbiomolbio.2018.08.001)
72. Rodero C *et al.* 2021 Linking statistical shape models and simulated function in the healthy adult human heart. *PLoS Comput. Biol.* **17**, e1008851. (doi:10.1371/journal.pcbi.1008851)
73. Strocchi M *et al.* 2023 Cell to whole organ global sensitivity analysis on a four-chamber heart electromechanics model using Gaussian processes emulators. *PLoS Comput. Biol.* **19**, e1011257. (doi:10.1371/journal.pcbi.1011257)
74. Regazzoni F, Quarteroni A. 2021 Accelerating the convergence to a limit cycle in 3D cardiac electromechanical simulations through a data-driven 0D emulator. *Comput. Biol. Med.* p. **135**, 104641. (doi:10.1016/j.compbimed.2021.104641)
75. Salvador M, Strocchi M, Regazzoni F. 2024 Whole-heart electromechanical simulations using Latent Neural Ordinary Differential Equations. *Npj Digital Medicine* **7**. (doi:10.1038/s41746-024-01084-x)
76. Yin M, Charon N, Brody R, Lu L, Trayanova N, Maggioni M. 2024 A scalable framework for learning the geometry-dependent solution operators of partial differential equations. *Nat. Comput. Sci.* **4**, 928–940. (doi:10.1038/s43588-024-00732-2)
77. König M, Grzegorzewski J, Golebiewski M. 2021 Ten simple rules for FAIR sharing of experimental and clinical data with the modeling community. *Preprints* (doi:10.20944/preprints202108.0303.v2)
78. Sauro HM, Agmon E, Blinov MV. 2025 From FAIR to CURE: Guidelines for Computational Models of Biological Systems. *Eprint* (doi:10.48550/arXiv.2502.15597)
79. Nagel C, Schuler S, Dössel O, Loewe A. 2021 A bi-atrial statistical shape model for large-scale *in silico* studies of human atria: model development and application to ECG simulations. *Med. Image Anal.* **74**, 102210. (doi:10.1016/j.media.2021.102210)
80. Strocchi M *et al.* 2020 A publicly available virtual cohort of four-chamber heart meshes for cardiac electro-mechanics simulations. *PLoS One* **15**, e0235145. (doi:10.1371/journal.pone.0235145)
81. Schuler S, Pilia N, Potyagaylo D, Loewe A. 2021 Cobiveco: consistent biventricular coordinates for precise and intuitive description of position in the heart – with MATLAB implementation. *Med. Image Anal.* **74**, 102247. (doi:10.1016/j.media.2021.102247)
82. Roney CH, Pashaei A, Meo M, Dubois R, Boyle PM, Trayanova NA, Cochet H, Niederer SA, Vigmond EJ. 2019 Universal atrial coordinates applied to visualisation, registration and construction of patient specific meshes. *Med. Image Anal.* **55**, 65–75. (doi:10.1016/j.media.2019.04.004)
83. Nairn D *et al.* 2023 Differences in atrial substrate localization using late gadolinium enhancement-magnetic resonance imaging, electrogram voltage, and conduction velocity: a cohort study using a consistent anatomical reference frame in patients with persistent atrial fibrillation. *Europace* **25**. (doi:10.1093/europace/euad278)
84. Dora S. 2012 *The San Francisco declaration on research assessment*. See <https://sfdora.org/read/> (accessed 27 April 2024).
85. Coalition for advancing research assessment. 2022 *The agreement on reforming research assessment*. See [https://coara.eu/app/uploads/2022/09/2022\\_07\\_19\\_rra\\_agreement\\_final.pdf](https://coara.eu/app/uploads/2022/09/2022_07_19_rra_agreement_final.pdf).
86. Anzt H *et al.* 2020 An environment for sustainable research software in Germany and beyond: current state, open challenges, and call for action. *F1000Res.* **9**, 295. (doi:10.12688/f1000research.23224.2)
87. Plank G *et al.* 2021 The openCARP simulation environment for cardiac electrophysiology. *Comput. Methods Programs Biomed.* **208**, 106223. (doi:10.1016/j.cmpb.2021.106223)
88. Africa PC, Piersanti R, Regazzoni F, Bucelli M, Salvador M, Fedele M, Pagani S, Dede' L, Quarteroni A. 2023 lifex-ep: a robust and efficient software for cardiac electrophysiology simulations. *BMC Bioinform.* **24**, 389. (doi:10.1186/s12859-023-05513-8)



89. Cooper F *et al.* 2020 Chaste: cancer, heart and soft tissue environment. *J. Open Source Softw.* **5**, 1848. (doi:10.21105/joss.01848)
90. Williams SE *et al.* 2021 OpenEP: a cross-platform electroanatomic mapping data format and analysis platform for electrophysiology research. *Front. Physiol.* **12**, 646023. (doi:10.3389/fphys.2021.646023)
91. Azzolin L, Schuler S, Dössel O, Loewe A. 2021 A reproducible protocol to assess arrhythmia vulnerability *in silico*: pacing at the end of the effective refractory period. *Front. Physiol.* **12**, 656411. (doi:10.3389/fphys.2021.656411)
92. Bach F, Klar J, Loewe A. 2022 The openCARP CDE – concept for and implementation of a sustainable collaborative development environment for research software. *Bausteine Forschungsdatenmanagement* 64–84. (doi:10.17192/bfdm.2022.1.8368)
93. Houillon M, Klar J, Stary T, Loewe A. 2023 *Automated software metadata conversion and publication based on CodeMeta*, pp. 228–234. Heidelberg, Germany: HeiBOOKS. (doi:10.11588/heibooks.1288.c18081)
94. Schreiber F *et al.* 2020 Specifications of standards in systems and synthetic biology: status and developments in 2020. *J. Integr. Bioinform.* **17**. (doi:10.1515/jib-2020-0022)
95. Brunak S, Bjerre Collin C, Eva Ó Cathaoir K, Golebiewski M, Kirschner M, Kockum I, Moser H, Waltemath D. 2020 Towards standardization guidelines for *in silico* approaches in personalized medicine. *J. Integr. Bioinform.* **17**, 20200006. (doi:10.1515/jib-2020-0006)
96. Clerx M, Cooling MT, Cooper J, Garny A, Moyle K, Nickerson DP, Nielsen PMF, Sorby H. 2020 CellML 2.0. *J. Integr. Bioinform.* **17**, 0021. (doi:10.1515/jib-2020-0021)
97. Hucka M *et al.* 2003 The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models. *Bioinformatics* **19**, 524–531. (doi:10.1093/bioinformatics/btg015)
98. Christie GR, Nielsen PMF, Blackett SA, Bradley CP, Hunter PJ. 2009 FieldML: concepts and implementation. *Philos. Trans. R. Soc.* **367**, 1869–1884. (doi:10.1098/rsta.2009.0025)
99. Bandrowski A, Grethe JS, Pilko A, Gillespie T, Pine G, Patel B, Surles-Zeigler M, Martone ME. 2021 SPARC data structure: rationale and design of a FAIR standard for biomedical research data. *bioRxiv*. (doi:10.1101/2021.02.10.430563)
100. Trevisan Jost T, Thangamani A, Colin R, Loechner V, Genaud S, Bramas B. 2023 GPU code generation of cardiac electrophysiology simulation with MLIR. In *Euro-par 2023: parallel processing*, pp. 549–563. Cham, Switzerland: Springer Nature Switzerland. (doi:10.1007/978-3-031-39698-4\_37)
101. Gsell MAF, Neic A, Bishop MJ, Gillette K, Prassl AJ, Augustin CM, Vigmond EJ, Plank G. 2024 ForCEPSS—a framework for cardiac electrophysiology simulations standardization. *Comput. Methods Programs Biomed.* **251**, 108189. (doi:10.1016/j.cmpb.2024.108189)
102. Babarenda Gamage T, Elsayed A, Lin C. 2023 Vision for the 12 LABOURS digital twin Platform. In *2023 45th Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC)*. Piscataway, NJ: IEEE. (doi:10.1109/EMBC40787.2023.10341138)
103. Virtual human twins manifesto. 2023 See <https://www.virtualhumantwins.eu/manifesto> (accessed 29 April 2024).
104. EDITH Consortium. 2023 EDITH CSA Deliverable 3.2: first draft of the VHT roadmap. *Zenodo* (doi:10.5281/ZENODO.8200954)
105. Bhagirath P, Strocchi M, Bishop MJ, Boyle PM, Plank G. 2024 From bits to bedside: entering the age of digital twins in cardiac electrophysiology. *Europace* **26**, euae295. (doi:10.1093/europace/euae295)
106. Updegrove A, Wilson NM, Merkow J, Lan H, Marsden AL, Shadden SC. 2017 SimVascular: an open source pipeline for cardiovascular simulation. *Ann. Biomed. Eng.* **45**, 525–541. (doi:10.1007/s10439-016-1762-8)
107. Yu T *et al.* 2011 The physiome model repository 2. *Bioinformatics* **27**, 743–744. (doi:10.1093/bioinformatics/btq723)
108. Lehman MM. 1980 Programs, life cycles, and laws of software evolution. *Proceedings of the IEEE* **68**, 1060–1076. (doi:10.1109/PROC.1980.11805)
109. Streckfuss-Bömeke K *et al.* 2024 Physiologists as medical scientists: an early warning from the German academic system. *Physiol. Rep.* **12**, e70055. (doi:10.14814/phy2.70055)



110. Trayanova NA, Lyon A, Shade J, Heijman J. 2024 Computational modeling of cardiac electrophysiology and arrhythmogenesis. *Physiol. Rev.* **104**, 2023. (doi:10.1152/physrev.00017.2023)
111. Quarteroni A, Lassila T, Rossi S, Ruiz-Baier R. 2017 Integrated heart—coupling multiscale and multiphysics models for the simulation of the cardiac function. *Comput. Methods Appl. Mech. Eng.* **314**, 345–407. (doi:10.1016/j.cma.2016.05.031)
112. Noble D. 1962 A modification of the hodgkin-huxley equations applicable to purkinje fibre action and pace-maker potentials. *J. Physiol.* **160**, 317–352. (doi:10.1113/jphysiol.1962.sp006849)
113. Nagel C, Espinosa CB, Gillette K, Gsell MAF, Sanchez J, Plank G, Dossel O, Loewe A. 2023 Comparison of propagation models and forward calculation methods on cellular, tissue and organ scale atrial electrophysiology. *IEEE Trans. Biomed. Eng.* **70**, 511–522. (doi:10.1109/tbme.2022.3196144)
114. Loewe A, Schulze WHW, Jiang Y, Wilhelms M, Luik A, Dössel O, Seemann G. 2015 ECG-based detection of early myocardial ischemia in a computational model: impact of additional electrodes, optimal placement, and a new feature for st deviation. *Biomed Res. Int.* **2015**, 530352. (doi:10.1155/2015/530352)
115. Dössel O, Luongo G, Nagel C, Loewe A. 2021 Computer modeling of the heart for ECG interpretation—a review. *Hearts* **2**, 350–368. (doi:10.3390/hearts2030028)
116. Boyle PM, Zahid S, Trayanova NA. 2017 Using personalized computer models to custom-tailor ablation procedures for atrial fibrillation patients: are we there yet? *Expert Rev. Cardiovasc. Ther.* **15**, 339–341. (doi:10.1080/14779072.2017.1317593)
117. Musuamba FT *et al.* 2021 Scientific and regulatory evaluation of mechanistic *in silico* drug and disease models in drug development: building model credibility. *CPT* **10**, 804–825. (doi:10.1002/psp4.12669)
118. Chabiniok R *et al.* 2016 Multiphysics and multiscale modelling, data–model fusion and integration of organ physiology in the clinic: ventricular cardiac mechanics. *Interface Focus* **6**, 20150083. (doi:10.1098/rsfs.2015.0083)
119. Emig R, Zgierski-Johnston CM, Timmermann V, Taberner AJ, Nash MP, Kohl P, Peyronnet R. 2021 Passive myocardial mechanical properties: meaning, measurement, models. *Biophys. Rev.* **13**, 587–610. (doi:10.1007/s12551-021-00838-1)
120. Göktepe S, Abilez OJ, Kuhl E. 2010 A generic approach towards finite growth with examples of athlete's heart, cardiac dilation, and cardiac wall thickening. *J. Mech. Phys. Solids* **58**, 1661–1680. (doi:10.1016/j.jmps.2010.07.003)
121. Quinn TA, Kohl P. 2021 Cardiac mechano-electric coupling: acute effects of mechanical stimulation on heart rate and rhythm. *Physiol. Rev.* **101**, 37–92. (doi:10.1152/physrev.00036.2019)
122. Gerach T *et al.* 2021 Electro-mechanical whole-heart digital twins: a fully coupled multiphysics approach. *Mathematics* **9**, 1247. (doi:10.3390/math9111247)
123. Fedele M, Piersanti R, Regazzoni F, Salvador M, Africa PC, Bucelli M, Zingaro A, Dede' L, Quarteroni A. 2023 A comprehensive and biophysically detailed computational model of the whole human heart electromechanics. *Comput. Methods Appl. Mech. Eng.* **410**, 115983. (doi:10.1016/j.cma.2023.115983)
124. Augustin CM, Neic A, Liebmann M, Prassl AJ, Niederer SA, Haase G, Plank G. 2016 Anatomically accurate high resolution modeling of human whole heart electromechanics: a strongly scalable algebraic multigrid solver method for nonlinear deformation. *J. Comput. Phys.* **305**, 622–646. (doi:10.1016/j.jcp.2015.10.045)
125. Gerach T, Loewe A. 2024 Differential effects of mechano-electric feedback mechanisms on whole-heart activation, repolarization, and tension. *J. Physiol.* (doi:10.1113/jp285022)
126. Bucelli M, Gabriel MG, Quarteroni A, Gigante G, Vergara C. 2023 A stable loosely-coupled scheme for cardiac electro-fluid-structure interaction. *J. Comput. Phys.* **490**, 112326. (doi:10.1016/j.jcp.2023.112326)
127. Brenneisen J, Daub A, Gerach T. 2021 A sequential coupling approach for fluid-structure interaction in a patient-specific whole-heart geometry. *Front. Cardiovasc. Med.* **8**, 768548. (doi:10.3389/fcvm.2021.768548)

128. Schwarz EL, Pegolotti L, Pfaller MR, Marsden AL. 2023 Beyond CFD: emerging methodologies for predictive simulation in cardiovascular health and disease. *Biophys. Rev.* **4**, 011301. (doi:10.1063/5.0109400)
129. Zingaro A, Fumagalli I, Dede L, Fedele M, Africa PC, Corno AF, Quarteroni A. 2022 A geometric multiscale model for the numerical simulation of blood flow in the human left heart. *Discret. Contin. Dyn. Syst. S* **15**, 2391. (doi:10.3934/dcdss.2022052)
130. Sánchez J, Loewe A. 2022 A review of healthy and fibrotic myocardium microstructure modeling and corresponding intracardiac electrograms. *Front. Physiol.* **13**, 908069. (doi:10.3389/fphys.2022.908069)
131. Moss R, Wülfers EM, Schuler S, Loewe A, Seemann G. 2021 A fully-coupled electromechanical whole-heart computational model: influence of cardiac contraction on the ECG. *Front. Physiol.* **12**, 778872. (doi:10.3389/fphys.2021.778872)
132. Loewe A, Krueger MW, Holmqvist F, Dössel O, Seemann G, Platonov PG. 2016 Influence of the earliest right atrial activation site and its proximity to interatrial connections on P-wave morphology. *Eur.* **18**, Europace. (doi:10.1093/europace/euw349)
133. Andlauer R, Seemann G, Baron L. 2018 Influence of left atrial size on P-wave morphology: differential effects of dilation and hypertrophy. *Europace* **20**, iii36–iii44. (doi:10.1093/europace/euy231)
134. Loewe A *et al.* 2019 Hypocalcemia-induced slowing of human sinus node pacemaking. *Biophys. J.* **117**, 2244–2254. (doi:10.1016/j.bpj.2019.07.037)
135. Amsaleg A, Sánchez J, Mikut R, Loewe A. 2022 Characterization of the pace-and-drive capacity of the human sinoatrial node: a 3D *in silico* study. *Biophys. J.* **121**, 4247–4259. (doi:10.1016/j.bpj.2022.10.020)
136. Loewe A, Lutz Y, Wilhelms M, Sinnecker D, Barthel P, Scholz EP, Dössel O, Schmidt G, Seemann G. 2014 *In silico* assessment of the dynamic effects of amiodarone and dronedarone on human atrial patho-electrophysiology. *Europace* **16**, iv30–iv38. (doi:10.1093/europace/euu230)
137. Wiedmann F *et al.* 2020 Pharmacologic TWIK-related acid-sensitive K<sup>+</sup> channel (TASK-1) potassium channel inhibitor A293 facilitates acute cardioversion of paroxysmal atrial fibrillation in a porcine large animal model. *J. Am. Heart Assoc.* **9**. (doi:10.1161/jaha.119.015751)
138. Passini E, Britton OJ, Lu HR, Rohrbacher J, Hermans AN, Gallacher DJ, Greig RJH, Bueno-Orovio A, Rodriguez B. 2017 Human *in silico* drug trials demonstrate higher accuracy than animal models in predicting clinical pro-arrhythmic cardiotoxicity. *Front. Physiol.* **8**, 668. (doi:10.3389/fphys.2017.00668)
139. Sager PT, Gintant G, Turner JR, Pettit S, Stockbridge N. 2014 Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the cardiac safety research consortium. *Am. Heart J.* **167**, 292–300. (doi:10.1016/j.ahj.2013.11.004)
140. Strauss DG, Wu WW, Li Z, Koerner J, Garnett C. 2021 Translational models and tools to reduce clinical trials and improve regulatory decision making for QTc and proarrhythmia risk (ICH E14/S7B updates). *Clin. Pharmacol. Ther.* **109**, 319–333. (doi:10.1002/cpt.2137)
141. Azzolin L *et al.* 2023 AugmentA: patient-specific augmented atrial model generation tool. *Comput. Med. Imaging Graph.* **108**, 102265. (doi:10.1016/j.compmedimag.2023.102265)
142. Solís-Lemus JA *et al.* 2023 Evaluation of an open-source pipeline to create patient-specific left atrial models: a reproducibility study. *Comput. Biol. Med.* **162**, 107009. (doi:10.1016/j.compbiomed.2023.107009)
143. Gillette K *et al.* 2021 A framework for the generation of digital twins of cardiac electrophysiology from clinical 12-leads ECGs. *Med. Image Anal.* **71**, 102080. (doi:10.1016/j.media.2021.102080)
144. Loewe A, Poremba E, Oesterlein T, Luik A, Schmitt C, Seemann G, Dössel O. 2018 Patient-specific identification of atrial flutter vulnerability—a computational approach to reveal latent reentry pathways. *Front. Physiol.* **9**, 1910. (doi:10.3389/fphys.2018.01910)
145. Niederer SA *et al.* 2020 Creation and application of virtual patient cohorts of heart models. *Philos. Transact. A Math. Phys. Eng. Sci.* **378**, 20190558. (doi:10.1098/rsta.2019.0558)
146. Roney CH *et al.* 2023 Constructing bilayer and volumetric atrial models at scale. *Interface Focus* **13**, 20230038. (doi:10.1098/rsfs.2023.0038)

147. Dasí A, Nagel C, Pope MTB, Wijesurendra RS, Betts TR, Sachetto R, Loewe A, Bueno-Orovio A, Rodriguez B. 2024 *in-Silico* TRIals guide optimal stratification of ATRial fibrillation patients to catheter ablation and pharmacological medication: the i-STRATIFICATION study. *Europace* **26**, euae150. (doi:10.1093/europace/euae150)
148. Shim J *et al.* 2017 Virtual *in silico* modeling guided catheter ablation predicts effective linear ablation lesion set for longstanding persistent atrial fibrillation: multicenter prospective randomized study. *Front. Physiol.* **8**, 792. (doi:10.3389/fphys.2017.00792)
149. Boyle PM *et al.* 2019 Computationally guided personalized targeted ablation of persistent atrial fibrillation. *Nat. Biomed. Eng.* **3**, 870–879. (doi:10.1038/s41551-019-0437-9)
150. Rodero C, Baptiste TMG, Barrows RK, Keramati H, Sillett CP, Strocchi M, Lamata P, Niederer SA. 2023 A systematic review of cardiac *in silico* clinical trials. *Prog. Biomed. Eng.* **5**, 032004. (doi:10.1088/2516-1091/acdc71)
151. Gerach T, Schuler S, Wachter A, Loewe A. 2023 The impact of standard ablation strategies for atrial fibrillation on cardiovascular performance in a four-chamber heart model. *Cardiovasc. Eng. Technol.* **14**, 296–314. (doi:10.1007/s13239-022-00651-1)
152. Azzolin L, Eichenlaub M, Nagel C, Nairn D, Sanchez J, Unger L, Dössel O, Jadidi A, Loewe A. 2023 Personalized ablation vs. conventional ablation strategies to terminate atrial fibrillation and prevent recurrence. *Europace* **25**, 211–222. (doi:10.1093/europace/euac116)
153. Gharaviri A, Pezzuto S, Potse M, Verheule S, Conte G, Krause R, Schotten U, Auricchio A. 2021 Left atrial appendage electrical isolation reduces atrial fibrillation recurrences. *Circulation* **14**. (doi:10.1161/circep.120.009230)
154. Alessandrini M, Valinoti M, Unger L, Oesterlein T, Dössel O, Corsi C, Loewe A, Severi S. 2018 A computational framework to benchmark basket catheter guided ablation in atrial fibrillation. *Front. Physiol.* **9**, 1251. (doi:10.3389/fphys.2018.01251)
155. Lehrmann H, Jadidi AS, Minners J, Chen J, Müller-Edenborn B, Weber R, Dössel O, Arentz T, Loewe A. 2018 Novel electrocardiographic criteria for real-time assessment of anterior mitral line block. *JACC* **4**, 920–932. (doi:10.1016/j.jacep.2018.03.007)
156. Monaci S *et al.* 2023 Non-invasive localization of post-infarct ventricular tachycardia exit sites to guide ablation planning: a computational deep learning platform utilizing the 12-lead electrocardiogram and intracardiac electrograms from implanted devices. *Europace* **25**, 469–477. (doi:10.1093/europace/euac178)
157. Frisch D, Oesterlein TG, Unger LA, Lenis G, Wakili R, Schmitt C, Luik A, Dossel O, Loewe A. 2020 Mapping and removing the ventricular far field component in unipolar atrial electrograms. *IEEE Trans. Biomed. Eng.* **67**, 2905–2915. (doi:10.1109/tbme.2020.2973471)
158. Vila M, Rivolta MW, Barrios Espinosa CA, Unger LA, Luik A, Loewe A, Sassi R. 2023 Recommender system for ablation lines to treat complex atrial tachycardia. *Comput. Methods Programs Biomed.* **231**, 107406. (doi:10.1016/j.cmpb.2023.107406)
159. Dasí A, Pope MTB, Wijesurendra RS, Betts TR, Sachetto R, Bueno-Orovio A, Rodriguez B. 2023 What determines the optimal pharmacological treatment of atrial fibrillation? Insights from *in silico* trials in 800 virtual atria. *J. Physiol.* **601**, 4013–4032. (doi:10.1113/jp284730)
160. Trovato C, Mohr M, Schmidt F. 2022 Cross clinical-experimental-computational qualification of *in silico* drug trials on human cardiac Purkinje cells for proarrhythmia risk prediction. *Br. J. Pharmacol.* **81**, 41–47. (doi:10.22541/au.164504834.41877071/v1)
161. Peirlinck M, Yao J, Sahli Costabal F, Kuhl E. 2022 How drugs modulate the performance of the human heart. *Comput. Mech.* **69**, 1397–1411. (doi:10.1007/s00466-022-02146-1)
162. Mill J. 2021 *In silico* analysis of the influence of pulmonary vein configuration on left atrial haemodynamics and thrombus formation in a large cohort. In *Functional imaging and modeling of the heart lecture notes in computer science*, pp. 605–616. Cham, Switzerland: Springer International Publishing. (doi:10.1007/978-3-030-78710-3\_58)
163. Doste R, Lozano M, Jimenez-Perez G, Mont L, Berruezo A, Penela D, Camara O, Sebastian R. 2022 Training machine learning models with synthetic data improves the prediction of ventricular origin in outflow tract ventricular arrhythmias. *Front. Physiol.* **13**, 909372. (doi:10.3389/fphys.2022.909372)
164. Nagel C, Luongo G, Azzolin L, Schuler S, Dössel O, Loewe A. 2021 Non-invasive and quantitative estimation of left atrial fibrosis based on P waves of the 12-lead ECG—a large-scale computational study covering anatomical variability. *J. Clin. Med.* **10**, 1797. (doi:10.3390/jcm10081797)

165. Nagel C, Schaufelberger M, Dössel O, Loewe A. 2022 A bi-atrial statistical shape model as a basis to classify left atrial enlargement from simulated and clinical 12-lead ECGs. In *Statistical atlases and computational models of the heart. multi-disease, multi-view, and multicenter right ventricular segmentation in cardiac MRI challenge*, pp. 38–47, vol. 13131. Springer: Lecture Notes in Computer Science. Cham, Switzerland. (doi:[10.1007/978-3-030-93722-5\\_5](https://doi.org/10.1007/978-3-030-93722-5_5))
166. Roney CH *et al.* 2022 Predicting atrial fibrillation recurrence by combining population data and virtual cohorts of patient-specific left atrial models. *Circ. Arrhythm. Electrophysiol.* **15**, e010253–e010253. (doi:[10.1161/CIRCEP.121.010253](https://doi.org/10.1161/CIRCEP.121.010253))
167. Shade JK, Ali RL, Basile D, Popescu D, Akhtar T, Marine JE, Spragg DD, Calkins H, Trayanova NA. 2020 Preprocedure application of machine learning and mechanistic simulations predicts likelihood of paroxysmal atrial fibrillation recurrence following pulmonary Vein isolation. *Circ. Arrhythm. Electrophysiol.* **13**, e008213. (doi:[10.1161/CIRCEP.119.008213](https://doi.org/10.1161/CIRCEP.119.008213))
168. Zhavoronkov A *et al.* 2019 Deep learning enables rapid identification of potent DDR1 kinase inhibitors. *Nat. Biotechnol.* **37**, 1038–1040. (doi:[10.1038/s41587-019-0224-x](https://doi.org/10.1038/s41587-019-0224-x))
169. Doste R, Camps J, Wang ZJ. 2025 An automated computational pipeline for generating large-scale cohorts of patient-specific ventricular models in electromechanical *In Silico* trials. *Eprint* (doi:[10.48550/arXiv.2503.03706v1](https://doi.org/10.48550/arXiv.2503.03706v1))
170. Zingaro A, Vergara C, Dede' L, Regazzoni F, Quarteroni A. 2023 A comprehensive mathematical model for cardiac perfusion. *Sci. Rep.* **13**. (doi:[10.1038/s41598-023-41312-0](https://doi.org/10.1038/s41598-023-41312-0))
171. Tikenogullari OZ, Peirlinck M, Chubb H, Dubin AM, Kuhl E, Marsden AL. 2024 Effects of cardiac growth on electrical dyssynchrony in the single ventricle patient. *Comput. Methods Biomech. Biomed. Eng.* **27**, 2023. (doi:[10.1080/10255842.2023.2222203](https://doi.org/10.1080/10255842.2023.2222203))
172. Hunter PJ, Ai W, Nickerson DP. 2025 Energy-based bond graph models of glucose transport with SLC transporters. *Biophys. J* **124**, 316–335. (doi:[10.1016/j.bpj.2024.12.006](https://doi.org/10.1016/j.bpj.2024.12.006))
173. Tveito A, Mardal K, Rognes M (eds). 2021 *Modeling excitable tissue*. Cham, Switzerland: Springer International Publishing. (doi:[10.1007/978-3-030-61157-6](https://doi.org/10.1007/978-3-030-61157-6))
174. Rosilho de Souza G, Krause R, Pezzuto S. 2024 Boundary integral formulation of the cell-by-cell model of cardiac electrophysiology. *Eng. Anal. Bound. Elem.* **158**, 239–251. (doi:[10.1016/j.enganabound.2023.10.021](https://doi.org/10.1016/j.enganabound.2023.10.021))
175. Pathmanathan P, Gray RA. 2018 Validation and trustworthiness of multiscale models of cardiac electrophysiology. *Front. Physiol.* **9**, 106. (doi:[10.3389/fphys.2018.00106](https://doi.org/10.3389/fphys.2018.00106))
176. Aldieri A, Curreli C, Szyszko JA, La Mattina AA, Viceconti M. 2023 Credibility assessment of computational models according to ASME V&V40: application to the bologna biomechanical computed tomography solution. *Comput. Methods Programs Biomed.* **240**, 107727. (doi:[10.1016/j.cmpb.2023.107727](https://doi.org/10.1016/j.cmpb.2023.107727))
177. Johnstone RH, Chang ETY, Bardenet R, de Boer TP, Gavaghan DJ, Pathmanathan P, Clayton RH, Mirams GR. 2016 Uncertainty and variability in models of the cardiac action potential: can we build trustworthy models? *J. Mol. Cell. Cardiol.* **96**, 49–62. (doi:[10.1016/j.yjmcc.2015.11.018](https://doi.org/10.1016/j.yjmcc.2015.11.018))
178. Unger L, Luik A, Azzolin L. 2021 Cycle length statistics during human atrial fibrillation reveal refractory properties of the underlying substrate - a combined in silico and clinical test of concept study. *Europace* **23**, i133–i142. (doi:[10.1093/europace/euaa404](https://doi.org/10.1093/europace/euaa404))
179. Kovacheva E, Thämer L, Fritz T, Seemann G, Ochs M, Dössel O, Loewe A. 2021 Estimating cardiac active tension from wall motion—an inverse problem of cardiac biomechanics. *Int. J. Numer. Methods Biomed. Eng.* **37**, e3448. (doi:[10.1002/cnm.3448](https://doi.org/10.1002/cnm.3448))
180. Coveney S, Roney CH, Corrado C, Wilkinson RD, Oakley JE, Niederer SA, Clayton RH. 2022 Calibrating cardiac electrophysiology models using latent Gaussian processes on atrial manifolds. *Sci. Rep.* **12**. (doi:[10.1038/s41598-022-20745-z](https://doi.org/10.1038/s41598-022-20745-z))
181. Coveney S, Cantwell C, Roney C. 2022 Atrial conduction velocity mapping: clinical tools, algorithms and approaches for understanding the arrhythmogenic substrate. *Med. Biol. Eng. Comput.* **60**, 2463–2478. (doi:[10.1007/s11517-022-02621-0](https://doi.org/10.1007/s11517-022-02621-0))
182. Camps J *et al.* 2024 Digital twinning of the human ventricular activation sequence to clinical 12-lead ECGs and magnetic resonance imaging using realistic Purkinje networks for *in silico* clinical trials. *Med. Image Anal.* **94**, 103108. (doi:[10.1016/j.media.2024.103108](https://doi.org/10.1016/j.media.2024.103108))



183. Martínez Díaz P, Dasí A, Goetz C, Unger LA, Haas A, Luik A, Rodríguez B, Dössel O, Loewe A. 2024 Impact of effective refractory period personalization on arrhythmia vulnerability in patient-specific atrial computer models. *Europace* **26**, euae215. (doi:10.1093/europace/euae215)
184. Martínez Díaz P, Sánchez J, Fitzen N, Ravens U, Dössel O, Loewe A. 2024 The right atrium affects in silico arrhythmia vulnerability in both atria. *Heart Rhythm* **21**, 799–805. (doi:10.1016/j.hrthm.2024.01.047)
185. Li L, Camps J, Rodriguez B, Grau V. 2025 Solving the inverse problem of electrocardiography for cardiac digital twins: a survey **18**, 316–336. (doi:10.1109/RBME.2024.3486439)
186. Pagani S, Dede' L, Manzoni A, Quarteroni A. 2021 Data integration for the numerical simulation of cardiac electrophysiology. *Pacing Clin. Electrophysiol.* **44**, 726–736. (doi:10.1111/pace.14198)
187. Mirams GR, Pathmanathan P, Gray RA, Challenor P, Clayton RH. 2016 Uncertainty and variability in computational and mathematical models of cardiac physiology. *J. Physiol.* **594**, 6833–6847. (doi:10.1113/jp271671)
188. Gray RA, Pathmanathan P. 2018 Patient-specific cardiovascular computational modeling: diversity of personalization and challenges. *J. Cardiovasc. Transl. Res.* **11**, 80–88. (doi:10.1007/s12265-018-9792-2)
189. Clayton RH *et al.* 2020 An audit of uncertainty in multi-scale cardiac electrophysiology models. *Philos. Transact. A Math. Phys. Eng. Sci.* **378**, 20190335. (doi:10.1098/rsta.2019.0335)
190. Winkler B, Nagel C, Farchmin N. 2023 Global sensitivity analysis and uncertainty quantification of synthetic atrial electrocardiogram data via polynomial chaos expansion. *Metrology* **3**, 1–28. (doi:10.3390/metrology3010001)
191. Karabelas E *et al.* 2022 Global sensitivity analysis of four chamber heart hemodynamics using surrogate models. *IEEE Trans. Biomed. Eng.* **69**, 3216–3223. (doi:10.1109/tbme.2022.3163428)
192. Bergquist JA, Zenger B, Rupp LC, Busatto A, Tate J, Brooks DH, Narayan A, MacLeod RS. 2023 Uncertainty quantification of the effect of cardiac position variability in the inverse problem of electrocardiographic imaging. *Physiol. Meas.* **44**, 105003. (doi:10.1088/1361-6579/acfc32)
193. Tate J *et al.* 2023 UncertainSCI: a Python package for noninvasive parametric uncertainty quantification of simulation pipelines. *J. Open Source Softw.* **8**, 4249. (doi:10.21105/joss.04249)
194. Barrios Espinosa C, Sánchez J, Appel S, Becker S, Krauß J, Martínez Díaz P, Unger L, Houillon M, Loewe A. 2025 A cyclical fast iterative method for simulating reentries in cardiac electrophysiology using an eikonal-based model. *Eng. Comput.* (doi:10.1007/s00366-024-02094-9)
195. Viceconti M, De Vos M, Mellone S, Geris L. 2024 Position paper from the digital twins in healthcare to the virtual human twin: a moon-shot project for digital health research. *IEEE J. Biomed. Health Informatics* **28**, 491–501. (doi:10.1109/jbhi.2023.3323688)
196. Bycroft C *et al.* 2018 The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**, 203–209. (doi:10.1038/s41586-018-0579-z)
197. Rodero C, Strocchi M, Marciniak M. 2021 Virtual cohort of 1000 synthetic heart meshes from adult human healthy population. *Zenodo* (doi:10.5281/zenodo.4506930)
198. La Mattina AA, Baruffaldi F, Taylor M, Viceconti M. 2023 Statistical properties of a virtual cohort for *in silico* trials generated with a statistical anatomy atlas. *Ann. Biomed. Eng.* **51**, 117–124. (doi:10.1007/s10439-022-03050-8)
199. Hellgren KT, Ni H, Morotti S, Grandi E. 2023 Predictive male-to-female translation of cardiac electrophysiological response to drugs. *JACC Clin. Electrophysiol.* **9**, 2642–2648. (doi:10.1016/j.jacep.2023.08.016)
200. Kohl P, Noble D. 2009 Systems biology and the virtual physiological human. *Mol. Syst. Biol.* **5**, 292. (doi:10.1038/msb.2009.51)
201. Hunter P *et al.* 2025 The physiome project and digital twins. *IEEE Rev. Biomed. Eng.* **18**, 300–315. (doi:10.1109/rbme.2024.3490455)